NeurologyLive® Mind Moments®

151: ECTRIMS 2025 Debrief: Precision MS & What’s Next with Daniel Ontaneda


Listen Later

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "ECTRIMS 2025 Meeting Highlights and Clinical Takeaways," Daniel Ontaneda, MD, PhD, neurologist at Cleveland Clinic’s Mellen Center for MS, shared his reflections from the 2025 ECTRIMS Congress, held September 24-26, in Barcelona, Spain. He discussed the significance of the updated MS diagnostic criteria, which generated immediate research applications and clinician discussion early in the meeting. Ontaneda also highlighted the growing emphasis on precision medicine and individualized treatment approaches, including extended-interval dosing strategies for B-cell therapies. In addition, he reviewed new therapeutic developments such as BTK inhibitors, CAR-T therapies, and remyelination research, noting both promising and disappointing data. Finally, he spoke on how ECTRIMS continues to expand beyond MS, with more presentations dedicated to NMOSD, MOGAD, and other autoimmune neurological conditions, reflecting the evolving landscape of neuroimmunology.


Looking for more Multiple Sclerosis discussion? Check out the NeurologyLive® Multiple Sclerosis clinical focus page.

Episode Breakdown:
  • 1:00 – Overall impressions of ECTRIMS 2025, highlighting diagnostic updates, precision medicine, and late-breaking trial results
  • 4:10 – Expanding focus on individualized care, especially interval-adjusted dosing strategies for B-cell therapies
  • 7:50 – Neurology News Minute
  • 9:50 – Insights on emerging therapeutic approaches including BTK inhibitors, CAR-T therapies, and remyelination strategies
  • 14:35 – Growing attention toward NMOSD, MOGAD, and other autoimmune conditions within neuroimmunology discussions

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits
    • Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
    • MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne

    • Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
      ...more
      View all episodesView all episodes
      Download on the App Store

      NeurologyLive® Mind Moments®By NeurologyLive

      • 4.6
      • 4.6
      • 4.6
      • 4.6
      • 4.6

      4.6

      10 ratings


      More shows like NeurologyLive® Mind Moments®

      View all
      NEJM This Week by NEJM Group

      NEJM This Week

      321 Listeners

      Neurology® Podcast by American Academy of Neurology

      Neurology® Podcast

      302 Listeners

      Practical Neurology Podcast by BMJ Group

      Practical Neurology Podcast

      49 Listeners

      The Clark Howard Podcast by Clark Howard

      The Clark Howard Podcast

      5,457 Listeners

      JAMA Neurology Author Interviews by JAMA Network

      JAMA Neurology Author Interviews

      12 Listeners

      BMJ Best Practice Podcast by BMJ Group

      BMJ Best Practice Podcast

      21 Listeners

      Neurology Today in 5 by American Academy of Neurology

      Neurology Today in 5

      25 Listeners

      Neurology Minute by American Academy of Neurology

      Neurology Minute

      133 Listeners

      Dateline NBC by NBC News

      Dateline NBC

      47,622 Listeners

      The Ezra Klein Show by New York Times Opinion

      The Ezra Klein Show

      16,096 Listeners

      Movers and Shakers: a podcast about life with Parkinson's by Podot

      Movers and Shakers: a podcast about life with Parkinson's

      106 Listeners

      Continuum Audio by American Academy of Neurology

      Continuum Audio

      80 Listeners

      Chanticleer by Australian Financial Review

      Chanticleer

      21 Listeners

      The Top Line by Fierce Life Sciences

      The Top Line

      13 Listeners

      The Economics Show by Financial Times

      The Economics Show

      140 Listeners